Origo Oncology Solution

Origo Oncology Solution

Workflow for Oncology Solution

Raw or Processed Genomic Data From Any MGS Platforms Using Any Panels

Built-in Bioinformatics Pipeline QC Standards Filtration Parameters

iCMDB

Variant Annotation Targeted Therapy Diagnosis Prognosis Clinical Trials

Oncology Solution Bioinformatics

Analyze and consolidate raw sequencing file and processed data from major NGS platforms.
Modularized, clinical application driven analysis with parameters dynamically tuned based on sample types and analysis purpose.
Support Docker, Fast Stallation

	# of Variants	Pipeline	Reported Variants	TP	FN	FP	Recall	Precision	F-score
SNV	276	Vishuo Oncology	261	261	15	0	94.57%	100.00%	97.21%
SNV	276	Standard Mutect2	262	261	15	1	94.57%	99.62%	97.03%
Indel	143	Vishuo Oncology	121	121	27	0	84.62%	100.00%	91.67%
Indel	143	Standard Mutect2	85	83	60	2	58.04%	97.65%	72.81%

Oncology Solution Origo

Scheduled data syncing and batch processing
Automatic QC and bioinformatics analysis
Informative data visualization and variant assessment
Integrative lab reporting functions
Seamless integration with the LIMS system
Clinical trials matching with automatic search and manual filtration.

Targeted Therapy with Benefit

Genomic Alteration Detected		FDA Approved	NCCN Guideline Recommended	FDA Approved in Other Tumor Type	Under Clinical Investigation	Under Pre-Clinical Investigation	Recruting Clinical Trial
Alteration	Frequency	FDA Approved	NCCN Guideline Recommended	FDA Approved in Other Tumor Type	Under Clinical Investigation	Under Pre-Clinical Investigation	Recruting Clinical Trial
EGFR p.L747_E749del Exon 19 Deletion	15.50%	Afatinib Erlotinib Gefitinib	Afatinib Erlotinib Gefitinib		AZD3759 (I) Sorafenib / Erlotinib (II)		Yes
ALK EML4-ALK Fusion	5.60%	Alectinib Certinib Crizotinib	Alectinib Certinib Crizotinib		Ensartinib Lortatinib	TAE684	Yes

Targeted Therapy with Resistance

Genomic Alteration Detected		FDA Approved	NCCN Guideline Recommended	FDA Approved in Other Tumor Type	Under Clinical Investigation	Under Pre-Clinical Investigation
Alteration	Frequency	FDA Approved	NCCN Guideline Recommended	FDA Approved in Other Tumor Type	Under Clinical Investigation	Under Pre-Clinical Investigation
KRAS p.G13D Exon 2-3 Mutation	4.50%		Afatinib Erlotinib Gefitinib

Disease Prognisis

Genomic Alteration Detected		NCCN Suggested	Expert Consensus	Clinical Investigation
Alteration	Frequency	NCCN Suggested	Expert Consensus	Clinical Investigation
TP53 p.E336*	6.20%			Controversial

Pharmacogenomics

Clinical Action	Drug	Gene	Genotype	Phenotype	Drug Resopnse			Evidence Level
Clinical Action	Drug	Gene	Genotype	Phenotype	Toxicity	Dosage	Efficacy	Evidence Level
	Platinum	KDR	A (RS1870377)	-	-	-		L3
	Cisplatin	TP53	GG (RS1042522)	-		-	-	L3

Do you need question?

Call us now to get free quotation
about your questions

Phone

+62 21-5433-1307

Whatsapp

+62815-3333-4940